Literature DB >> 6968292

Mitogenic activity of two Brucella fractions for murine B lymphocytes.

J P Vendrell, A Escande, A Cannat, M F Huguet, A Serre.   

Abstract

Two lipid A-free fractions extracted from Brucella melitensis (fractions PI and SF) were shown to behave as B-cell non-specific mitogens for murine lymphocytes: they stimulated the uptake of tritiated thymidine by normal unsensitized murine splenic lymphocytes, by spleen cells from nude mice and by T-cell depleted but not by T-cell enriched and B-cell-deprived splenic populations. Since depletion of adherent cells leads to a two- to three-fold depression of PI- or SF-induced mitogenic responses these two fractions were shown to require accessory adherent cell participation for an optimal mitogenicity. Moreover they behaved as polyclonal activators for murine spleen cells. These results are discussed in terms of a possible classification of PI and SF amongst other B-cell mitogens and of the respective role of the peptidoglycan and lipoprotein moieties in B-cell activation by Brucella fractions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968292      PMCID: PMC1458483     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

2.  [Anti-brucellosis human vaccination with an antigenic fraction of Brucella melitensis].

Authors:  J Roux; A Serre; J Asselineau; C Lacave
Journal:  Bull Acad Natl Med       Date:  1970 Apr-May       Impact factor: 0.144

3.  T and CR+ lymphocyte profile in leprosy and the effect of treatment.

Authors:  R Sher; G Holm; S H Kok; H J Koornhof; A Glover
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

4.  Absolute macrophage dependency of T lymphocyte activation by mitogens.

Authors:  D L Rosenstreich; J J Farrar; S Dougherty
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

5.  Physical state and biological activity of lipopolysaccharides. Toxicity and immunogenicity of the lipid A component.

Authors:  C Galanos
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1975-07

6.  Characterization of the chemical and physical properties of a novel B-lymphocyte activator, endotoxin protein.

Authors:  G W Goodman; B M Sultzer
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

7.  Macrophages are required for the dextran-sulfate induced activation of B lymphocytes.

Authors:  U C Persson; L L Hammarström; C I Smith
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

8.  Some structural and biological properties of Brucella endotoxin.

Authors:  D Leong; R Diaz; K Milner; J Rudbach; J B Wilson
Journal:  Infect Immun       Date:  1970-02       Impact factor: 3.441

9.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

10.  The peritoneal exudate lymphocyte. I. Differences in antigen responsiveness between peritoneal exudate and lymph node lymphocytes from immunized guinea pigs.

Authors:  D L Rosenstreich; J T Blake; A S Rosenthal
Journal:  J Exp Med       Date:  1971-11-01       Impact factor: 14.307

View more
  3 in total

1.  In vitro studies on the adjuvanticity of Brucella fractions.

Authors:  A Serre; J P Vendrell; M F Huguet; A Cannat
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

2.  Brucella fractions behave as nonspecific mitogens and polyclonal B-cell activators for human lymphocytes.

Authors:  J P Vendrell; H Rabesandratana; M F Huguet; A Cannat; A Serre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

3.  Immune serum-mediated effects on brucellosis evolution in mice.

Authors:  M Plommet; A M Plommet
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.